ClinicalTrials.gg
CompletedNCT01904149DAVID lapUpdated Apr 1, 2016Results posted

Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride

A Phase 3 interventional study of Placebo and Dexketoprofen-single dose in Acute Pain, sponsored by Menarini Group. Completed at 28 sites in 8 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-04-01.

Sponsored by Menarini Group · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
606
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Acute Pain with a site in Poland — 1 open to participants now, 1 under way, none of them phase 3. Acute Pain · Poland.

Enrollment
5th of 18
606 · median 158
Started
2013
with 1 other
Phase 3
6 of 19
none open now
Registered
2nd of 19
by date
Lead sponsor
3 of 19
Menarini Group

Among the 19 studies in Acute Pain with a site in Poland, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2013, is one of 6 in phase 3, and was the 2nd registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

1 of the 19 studies in Acute Pain with a site in Poland is open now. Recruiting first, the newest first:

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Acute Pain with a site in Poland, or all of them as a file.
02

Study summary

This study aims to evaluate the analgesic efficacy of single and repeated doses of fixed combination of dexketoprofen trometamol (DKP) and tramadol hydrochloride (TRAM) in comparison to the single agents (and placebo for the single dose phase only).

Approximately 600 female patients presenting moderate to severe pain after a total/subtotal abdominal hysterectomy are eligible to be randomised provided that they experience moderate to severe pain on the day after surgery.

Read the detailed description

In this clinical trial patients were randomized to the described 6 treatment arms, where each arm define the treatment to be received in the first single dose phase (lasting 8 hours after the 1st treatment intake) and in the subsequent multiple-dose phase (lasting from the second treatment intake up to the 8 hours after the last intake). Namely:

  • DKP/TRAM followed by DKP/TRAM;
  • DKP followed by DKP;
  • TRAM followed by TRAM;
  • placebo followed by DKP;
  • placebo followed by TRAM;
  • placebo followed by DKP/TRAM;

The analyses of endpoints pertinent to the single dose phase were performed combining all the 3 treatment arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.

The analysis of endpoints pertinent to the multiple dose phase were performed combining the treatment arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.

03

Conditions studied

  • Acute Pain

Keywords

  • Moderate to severe acute pain
  • Postoperative pain
  • Abdominal hysterectomy
  • Analgesics
  • Dexketoprofen
  • Tramadol
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 to 75 years.
  • Scheduled to undergo a total or subtotal abdominal hysterectomy (with or without salpingo-oophorectomy) for benign conditions.
  • Patients experiencing pain at rest of at least moderate intensity the day after surgery.

Exclusion criteria

Exclusion Criteria:

  • Patients not suitable for study treatments and rescue medication (RM) or those for whom non-steroidal anti-inflammatory drugs (NSAIDs), opioids, acetyl salicylic acid, pyrazolones or pyrazolidines are .
  • Patients with abnormalities in vital signs, safety laboratory tests and 12-lead at screening.
  • Patients with history of any illness or condition that might pose a risk to the patient or confound the efficacy and safety study results.
  • Patients using and not suitable to withdraw analgesics other than those specified in the protocol.
  • Patients using and not suitable for withdrawing any of the prohibited medication specified in the protocol.
  • Breastfeeding women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
606 participants (actual)

Study arms

  • Experimental
    DKP/TRAM followed by DKP/TRAM

    Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses

    Drug: Dexketoprofen/Tramadol-single dose · Drug: Dexketoprofen/Tramadol-multiple doses

  • Active comparator
    DKP followed by DKP

    Dexketoprofen-single dose followed by Dexketoprofen-multiple doses

    Drug: Dexketoprofen-single dose · Drug: Dexketoprofen-multiple doses

  • Active comparator
    TRAM followed by TRAM

    Tramadol-single dose followed by Tramadol-multiple doses

    Drug: Tramadol-single dose · Drug: Tramadol-multiple doses

  • Other
    Placebo followed by DKP/TRAM

    Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses

    Drug: Placebo · Drug: Dexketoprofen/Tramadol-multiple doses

  • Other
    Placebo followed by DKP

    Placebo single dose followed by Dexketoprofen-multiple doses

    Drug: Placebo · Drug: Dexketoprofen-multiple doses

  • Other
    Placebo followed by TRAM

    Placebo single dose followed by Tramadol-multiple doses

    Drug: Placebo · Drug: Tramadol-multiple doses

Interventions

  • DrugPlacebo

    Placebo single oral dose (first 8 hours)

  • DrugDexketoprofen-single dose

    Dexketoprofen single oral dose (first 8 hours)

  • DrugTramadol-single dose

    Tramadol single oral dose (first 8 hours)

  • DrugDexketoprofen/Tramadol-single dose

    Dexketoprofen/Tramadol single oral dose (first 8 hours)

  • DrugDexketoprofen-multiple doses

    Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)

  • DrugTramadol-multiple doses

    Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)

  • DrugDexketoprofen/Tramadol-multiple doses

    Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)

06

What researchers measure

Primary outcomes

  1. SPID8 (Sum of Pain Intensity Differences Over 8 Hours)

    Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.

    Time frame: over 8 hours after the first dose

Secondary outcomes

  1. Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)

    Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief - Verbal Rating Scale: pain relief 0=none, 4=complete) scores. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.

    Time frame: over 8 hours after first dose

  2. SPID48 (Sum of Pain Intensity Differences Over 48 Hours of the Multiple-dose Phase)

    Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.

    Time frame: over 48 hours of the multiple-dose phase

  3. Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)

    Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS \< 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable), over 48 hours of the multiple-dose phase. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.

    Time frame: over 48 hours of the multiple-dose phase

07

Results

Posted Apr 1, 2015

Participant flow

Participant flow — Overall Study
MilestoneDKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAM
Started152151150515151
Single-dose phase152151150515151
Multiple-dose phase150146149484849
Completed147140148474648
Not completed5112453
Withdrew: Adverse event340112
Withdrew: Lack of efficacy031331
Withdrew: Withdrawal by subject131010
Withdrew: Protocol violation010000
Withdrew: Non compliance with study drug100000

Outcome measures

PrimarySPID8 (Sum of Pain Intensity Differences Over 8 Hours)

Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.

Time frame:
over 8 hours after the first dose
Reported as:
Mean · units on a scale
SPID8 (Sum of Pain Intensity Differences Over 8 Hours)
units on a scaleDKP/TRAMDEXKETOPROFENTRAMADOLPLACEBO
SPID8 (Sum of Pain Intensity Differences Over 8 Hours)241.8 ± 139.06184.5 ± 139.23157.3 ± 150.89117.0 ± 121.80
SecondaryPercentage of Responders According to 50% Max TOTPAR (Total Pain Relief)

Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief - Verbal Rating Scale: pain relief 0=none, 4=complete) scores. The analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.

Time frame:
over 8 hours after first dose
Reported as:
Number · percentage of participants
Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)
percentage of participantsDKP/TRAMDEXKETOPROFENTRAMADOLPLACEBO
Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)65.847.744.030.7
SecondarySPID48 (Sum of Pain Intensity Differences Over 48 Hours of the Multiple-dose Phase)

Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.

Time frame:
over 48 hours of the multiple-dose phase
Reported as:
Mean · units on a scale
SPID48 (Sum of Pain Intensity Differences Over 48 Hours of the Multiple-dose Phase)
units on a scaleDKP/TRAMDEXKETOPROFENTRAMADOL
SPID48 (Sum of Pain Intensity Differences Over 48 Hours of the Multiple-dose Phase)2273.0 ± 864.031965.2 ± 912.192035.0 ± 919.49
SecondaryPercentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)

Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS \< 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable), over 48 hours of the multiple-dose phase. The analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.

Time frame:
over 48 hours of the multiple-dose phase
Reported as:
Number · percentage of participants
Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)
percentage of participantsDKP/TRAMDEXKETOPROFENTRAMADOL
Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)94.182.788.6

Adverse events

Collected over Study duration for patients was up to 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DKP/TRAM Followed by DKP/TRAM—7/151 (4.6%)22/151 (14.6%)
DKP Followed by DKP—2/152 (1.3%)22/152 (14.5%)
TRAM Followed by TRAM—1/150 (0.7%)33/150 (22%)
Placebo Followed by DKP/TRAM—0/52 (0%)3/52 (5.8%)
Placebo Followed by DKP—0/50 (0%)10/50 (20%)
Placebo Followed by TRAM—0/51 (0%)10/51 (19.6%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventDKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAM
Fallopian tube torsionReproductive system and breast disorders0/1510/1521/1500/520/500/51
Ovarian torsionReproductive system and breast disorders0/1510/1521/1500/520/500/51
LaparotomySurgical and medical procedures0/1510/1521/1500/520/500/51
Endometrial cancer stage IReproductive system and breast disorders0/1510/1521/1500/520/500/51
Post procedural haemorrhageInjury, poisoning and procedural complications1/1511/1520/1500/520/500/51
Abdominal wound dehiscenseInjury, poisoning and procedural complications1/1510/1520/1500/520/500/51
Anaemia postoperativeInjury, poisoning and procedural complications1/1510/1520/1500/520/500/51
abdominal pain lowerGastrointestinal disorders1/1510/1520/1500/520/500/51
diarrhoeaGastrointestinal disorders1/1510/1520/1500/520/500/51
peritoneal haematomaGastrointestinal disorders1/1510/1520/1500/520/500/51
Most frequent other events
Most frequent other events
EventDKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAM
NauseaGastrointestinal disorders9/1516/15214/1503/522/505/51
Platelet count increasedInvestigations3/1518/1529/1500/523/503/51
Blood lactate dehydrogenase increasedInvestigations1/1512/1522/1500/523/500/51
ConstipationGastrointestinal disorders6/1512/1526/1500/522/503/51
VomitingGastrointestinal disorders5/1516/1528/1500/520/500/51

Baseline characteristics

Intention-to-treat (ITT) population (which includes all patients randomized).

Age, Continuous
Age, Continuous(years)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
Mean48.1 ± 6.7047.2 ± 7.0747.6 ± 6.8747.4 ± 6.8247.4 ± 7.4647.2 ± 4.6047.6 ± 6.75
Sex/Gender, Customized
Sex/Gender, Customized(participants)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
Females152151150515151606
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
White152151150515151606
Region of Enrollment
Region of Enrollment(participants)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
Hungary22192687789
Slovakia713852439
Spain1210015
Poland635360182317234
Romania324032101212138
Lithuania24311314
Russian Federation33322215
Latvia22171774572
Weight
Weight(kg)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
Mean75.2 ± 15.1572.1 ± 13.5471.3 ± 12.1773.6 ± 13.7472.9 ± 14.6072.6 ± 10.9772.9 ± 13.58
Height
Height(cm)DKP/TRAM Followed by DKP/TRAMDKP Followed by DKPTRAM Followed by TRAMPlacebo Followed by DKP/TRAMPlacebo Followed by DKPPlacebo Followed by TRAMTotal
Mean163.9 ± 5.40163.7 ± 6.37164.1 ± 6.10164.5 ± 6.17163.5 ± 5.94164.4 ± 5.59164.0 ± 5.94
08

Study locations

28 sites
  • Bajcsy-Zsilinszky Kórház
    Budapest, 1106, Hungary
  • University Hospital of Debrecen
    Debrecen, H-4012, Hungary
  • Dr. Bugyi István Kórház
    Szentes, H-6600, Hungary
  • Fejér megyei Szent György Kórház
    Székesfehérvár, 8000, Hungary
  • Juras Medicinas Centre
    Riga, LV-1005, Latvia
  • Riga East University Hospital Gynecology Clinic
    Riga, LV-1038, Latvia
  • Hospital of Lithuanian University of Health Sciences Kaunas
    Kaunas, LT-50009, Lithuania
  • Vilniaus gimdymo namai
    Vilnius, LT-02106, Lithuania
  • Samodzielny Publiczny Szpital Kliniczny nr 1
    Lublin, Lubelskie 20-081, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
    Lublin, Lubelskie 20-954, Poland
  • Prywatna Klinika Polozniczo-Ginekologiczna
    Bialystok, 15-224, Poland
  • Ginekologiczno-Polożniczy Szpital Kliniczny UM w Poznaniu
    Poznan, 60-535, Poland
  • Wojewodzki Szpital
    Przemyśl, 37-700, Poland
  • Specjalistyczny Szpital im. E. Szczeklika
    Tarnow, 33-100, Poland
  • Wojskowy Instytut Medyczny, Centralny Szpital Kliniczny Mini
    Warszawa, 00-909, Poland
  • Centralny Szpital Kliniczny MSW w Warszawie
    Warszawa, 02-507, Poland
  • Institutul pentru Ocrotirea Mamei si Copilului (IOMC) "Prof. Dr. Alfred Rusescu"
    Bucharest, 011062, Romania
  • Genesys Fertility Center
    Bucharest, 011475, Romania
  • Spitalul Clinic "Dr. Ioan Cantacuzino" - Sectia Clinica Obstetrica Ginecologie II
    Bucharest, 020475, Romania
  • Spitalul Clinic "Dr. Ioan Cantacuzino" - Sectia Clinica Obstetrica Ginecologie I
    Bucharest, 020475, Romania
  • Spitalul Universitar de Urgenta Bucuresti
    Bucharest, 050098, Romania
  • Spitalul Clinic de Urgenta "Sfantul Pantelimon"
    Bucuresti, 21623, Romania
  • Spitalul Clinic Judetean de Urgenta Targu Mures - Sectia Obstretica Ginecologie I
    Targu-Mures, 540136, Romania
  • Moscow Regional Research Institute of Obstetrics and Gynecol
    Moscow, 101000, Russian Federation
  • FGUZ Clinical Hospital 122 n.a. L.G. Sokolova FMBA
    Saint Petersburg, 194291, Russian Federation
  • GYNPOR, s.r.o.
    Sliac, 962-31, Slovakia
  • Complejo Hospitalario Arquitecto Marcide
    Ferrol, 15405, Spain
  • Hospital Universitario Arnau de Vilanova
    Lérida, 25198, Spain
09

References and documents

Publications

  • Moore RA, McQuay HJ, Tomaszewski J, Raba G, Tutunaru D, Lietuviete N, Galad J, Hagymasy L, Melka D, Kotarski J, Rechberger T, Fulesdi B, Nizzardo A, Guerrero-Bayon C, Cuadripani S, Piza-Vallespir B, Bertolotti M. Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy. BMC Anesthesiol. 2016 Jan 22;16:9. doi: 10.1186/s12871-016-0174-5. Erratum In: BMC Anesthesiol. 2017 Nov 30;17(1):159. doi: 10.1186/s12871-017-0452-x. PubMed 26801905 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2013
First posted
Jul 22, 2013
Start
May 2013
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
Apr 1, 2015
Last update
Apr 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01904149
Lead sponsor
Menarini Group
Responsible party
Sponsor
First posted
Jul 22, 2013
Start date
May 2013
Primary completion
May 2014
Completion
May 2014
Results posted
Apr 1, 2015
Last update
Apr 1, 2016

Study contacts

Henry J McQuay, Professor
study chair · Balliol College Oxford
Andrew Moore, Professor
study chair · Pain Research & Nuffield Department of Anaesthetics - University of Oxford

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion